Crispr Therapeutics AG Receives Buy Rating and $56 Price Target from Leerink Partners

Crispr Therapeutics AG (CRSP) has received a Buy rating from Leerink Partners with a price target of $56.00. The analyst, Mani Foroohar, has a 43.25% success rate and an average return of -7.6%. The company reported a quarterly revenue of $892 thousand and a GAAP net loss of $208.55 million in its latest earnings release. Based on corporate insider activity, sentiment is positive, with 21 insiders buying their shares over the past quarter.

CRISPR Therapeutics AG (CRSP) has received a Buy rating from Leerink Partners with a price target of $56.00. The analyst, Mani Foroohar, has a 43.25% success rate and an average return of -7.6%. The company reported a quarterly revenue of $892 thousand and a GAAP net loss of $208.55 million in its latest earnings release. Based on corporate insider activity, sentiment is positive, with 21 insiders buying their shares over the past quarter.

In a recent research note, Leerink Partners decreased its Q3 2025 earnings per share (EPS) estimate for CRISPR Therapeutics from ($1.59) to ($1.62), reflecting a cautious outlook for the company's financial performance [1]. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partners also issued estimates for CRISPR Therapeutics' Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($5.52) EPS and FY2026 earnings at ($5.53) EPS.

The stock has seen mixed analyst sentiment, with a majority of analysts issuing a "buy" rating. However, several analysts have reduced their target prices. Barclays boosted their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating. Piper Sandler restated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics. Bank of America dropped their target price on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company. HC Wainwright boosted their target price on CRISPR Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating. Royal Bank Of Canada upped their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating [1].

Several institutional investors and hedge funds have recently modified their holdings of CRSP. ARK Investment Management LLC boosted its position in CRISPR Therapeutics by 13.3% during the first quarter. Capital International Investors boosted its position in CRISPR Therapeutics by 10.3% during the fourth quarter. T. Rowe Price Investment Management Inc. boosted its position in CRISPR Therapeutics by 39.2% during the fourth quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in CRISPR Therapeutics by 182.9% during the first quarter. Vanguard Group Inc. boosted its position in CRISPR Therapeutics by 1.9% during the first quarter. 69.20% of the stock is owned by institutional investors and hedge funds [1].

CRISPR Therapeutics has reported a 71.6% year-over-year revenue increase, yet posted a loss of ($1.58) per share, missing consensus estimates. Banque Cantonale Vaudoise acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 18,579 shares of the company's stock, valued at approximately $632,000. Several other large investors also recently modified their holdings of CRSP. LPL Financial LLC boosted its stake in CRISPR Therapeutics by 39.3% in the fourth quarter. Vanguard Group Inc. grew its holdings in shares of CRISPR Therapeutics by 0.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in CRISPR Therapeutics by 7.6% during the 4th quarter. Norges Bank bought a new position in CRISPR Therapeutics in the 4th quarter valued at approximately $17,458,000. Finally, ExodusPoint Capital Management LP acquired a new stake in CRISPR Therapeutics in the fourth quarter [2].

The company's stock opened at $56.34 on Thursday and has a market cap of $4.87 billion, a P/E ratio of -10.38 and a beta of 1.80. The business's fifty day moving average is $50.83 and its two-hundred day moving average is $43.72. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $71.13. The company is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

References:
[1] https://www.marketbeat.com/instant-alerts/leerink-partnrs-has-pessimistic-view-of-crsp-q3-earnings-2025-08-07/
[2] https://www.marketbeat.com/instant-alerts/filing-banque-cantonale-vaudoise-purchases-shares-of-18579-crispr-therapeutics-ag-nasdaqcrsp-2025-08-02/